Potential predictors of placebo response: Lessons from a large database

Drug Information Journal

Volumn 41, Issue 3, 2007, Pages 315-330

  Entsuah, Richard ^a   Vinall, Phil ^a  

^a PFIZER INC   (United States)

Author keywords

Depression; Placebo response; Statistical analyses; Study design

Indexed keywords

AMITRIPTYLINE; IMIPRAMINE; PLACEBO; TRAZODONE; VENLAFAXINE;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DEMOGRAPHY; DISEASE DURATION; DRUG DOSE REDUCTION; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MATHEMATICAL MODEL; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REMISSION; STATISTICAL ANALYSIS; UNIVARIATE ANALYSIS;

EID: 34248374306     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150704100304     Document Type: Article

References (47)

1. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies with major depression: variable, substantial, and growing. JAMA. 2002;287:1840-1847.
2. Brown WA. Placebo as a treatment for depression. Neuropsychopharmacology. 1994;10:265-293.
3. Trivedi MH, Rush H. Does a placebo run-in or a placebo treatment cell affect the efficacy of anti-depressant medications? Neuropsychopharmacology. 1994;11:33-43.
4. Brown WA. The placebo effect. Sci Am. 1998;278:90-95.
5. Quitkin FM, Fabkin JG, Gerald J, Davis JM, Klein DF. Validity of clinical trials of antidepressants. Am J Psychiatry. 2000;157:327-337.
6. Leber P. The use of placebo control groups in the assessment of psychiatric drugs: an historical context. Biol Psychiatry. 2000;47:688-706.
7. Brown WA. Clinical features of depressed patients who do and do not improve with placebo. Psychiatry Res. 1992;41:203-214.
8. Fairchild CJ, Rush JA, Versavada N, Giles DE, Khatami M. Which depressions respond to placebo? Psychiatry Res. 1986;18:217-226.
9. Paykel ES, Hollyman JA, Freeling P, Sedwick P. Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. J Affect Disord. 1988;14:83-95.
10. Stewart JW, Quitkin FM, Liebowitz MR, McGrath PJ, Harrison WM, Klein DF. Efficacy of desipramine in depressed outpatients. Arch Gen Psychiatry. 1983;55:334-343.
11. Wilcox CS, Cohn JB, Linden RD, et al. Predictors of placebo response: a retrospective analysis. Psy chopharmacol Bull. 1992;28:157-162.
12. Schatzberg AF. Determinants of placebo response rates in clinical trials. Paper presented at: 35th New Clinical Drug Evaluation Unit, May-June 1995; Orlando, FL.
13. Khan A, Dager SR, Chohen S, Avery DH, Scherzo B, Dunner DL. Chronicity of depressive episode in relation to antidepressant-placebo response. Neuropsychopharmacology. 1991;4:125-130.
14. Thase ME. Long-term treatments of recurrent depressive disorders. J Clin Psychiatry. 1992;53:32-44.
15. Fava GA, Grandi S, Zielezny M, et al. Four year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry. 1996;153:945-947
16. Miller IW, Keitner GI, Schatzberg AF, et al. Treatment of chronic depression, III: psychosocial functioning before and after treatment with sertraline or impramine. J Clin Psychiatry. 1998;59:608-619.
17. Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychpharmacol. 1994;9:139-143.
18. Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuro-Psychopharmacol Biol Psychiatry. 1996;20:57-71.
19. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord. 1999;56:171-181.
20. Silverstone PH, Ravindran AV. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry. 1999;60:22-28.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed., rev. Washington, DC: American Psychiatric Association; 1987
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
23. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
24. Thase ME, Friedman ES, Howland RH. Venlafaxine and treatment-resistant depression. Depression Anxiety. 2000;12(suppl 1):55-62.
25. Frank JD, Frank JE. Persuasion and Healing: A Comparative Study of Psychotherapy. London: Johns Hopkins University Press; 1991.
26. Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: an analysis of the food and drug administration database. J Clin Psychopharmacol. 2002;22:40-45.
27. Rush JA. The use of placebos in unipolar major depression: the current status. Biol Psychiatry. 2000;47:745-747
28. Brown WA, Dornseif BE, Wernicke JF. Placebo response in depression: a search for predictors. Psychiatry Res. 1988;26:259-264.
29. Miller CA, Hooper CL, Bakish D. A comparison of placebo response with major depressive disorder in patients recruited through newspaper advertising versus consultation referrals. Psychopharmacol Bull. 1997;33:647-651.
30. Brown WA. Predictors of placebo response in depression. Psychopharmacol Bull. 1988;24:14-17
31. Khan A, Brown WA. Who should receive antidepressants: suggestions from placebo treatment. Psychopharmacol Bull. 1991;27:271-274.
32. Hildebrandt MG, Steyerberg EW, Stage KB, Passchier J, Kragh-Soerensen P, Group DUA. Are gender differences important for the clinical effects of antidepressants? Am J Psychiatry. 2003;160:1643-1650.
33. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000;157:1445-14452.
34. Davidson J, Pelton S. Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res. 1986;17:87-95.
35. Bailik RJ, Ravindran AV, Bakish D, Lapierre YD. A comparison of placebo responders and nonresponders in subgroups of depressive disorder. J Psychiatry Neurosci. 1995;20:265-270.
36. Quitkin FM, Stewart JW McGrath PJ, et al. Are there differences between women's and men's antidepressant responses? Am J Psychiatry. 2002;157:1848-1854.
37. Greenberg RP, Bornstein RF, Greenberg MD, Fisher S. A meta-analysis of antidepressant outcome under "blinder" conditions. J Consult Clin Psychol. 1992;60:664-669.
38. Quitkin FM, Rabkin JD, Markowitz JM, Stewart JW, McGrath PJ, Harrison W. Use of pattern analysis to identify true drug response. Arch Gen Psychiatry. 1987;44:259-264.
39. Horwitz RI, Horwitz SM. Adherence to treatment and health outcomes. Arch Intern Med. 1993;153:1863-1868.
40. Greist JH, Mundt JC, Kobak K. Factors contributing to failed trials of new agents: can technology prevent some problems? J Clin Psychiatry. 2002;63(suppl 2):8-13.
41. Margraf J, Ehlers A, Roth WT, et al. How "blind" are double-blind studies? J Consult Clin Psychol. 1991;59:184-187.
42. Fisher S, Greenberg RP. How sound is the double-blind design for evaluating psychotropic drugs. J Nerv Ment Dis. 1993;181:345-350.
43. Reimherr FW, Ward MF, Byerley WF. The introductory placebo washout: a retrospective evaluation. Psychiatry Res. 1989;30:191-199.
44. Bambauer KZ, Onesky A, Stone PH, et al. The effect of telephone counseling intervention on self-rated health of cardiac patients. Psychosom Med. 2005;67:539-545.
45. Fava GA, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psy chother Psychosom. 2003;72:115-127.
46. Yao Q, Wei LJ. Play the winner for phase II/III clinical trials. Stat Med. 1996;15:2413-2423.
47. Rosenberger WF, Hu F. Bootstrap methods for adaptive designs. Stat Med. 1999;18:1757-1767.